What is Epitalon?
Epitalon (also rendered Epithalon in some publications) is a synthetic tetrapeptide with the sequence alanine-glutamic acid-aspartic acid-glycine, abbreviated AEDG. Its molecular weight is approximately 431 Da. The compound was developed at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson as a synthetic analog of Epithalamin, a polypeptide fraction extracted from bovine pineal gland tissue.
Epithalamin was the subject of Soviet and Russian clinical programs beginning in the 1970s. Epitalon was designed as a chemically defined, reproducible version of the active fraction, eliminating the batch variability inherent in biological extracts. The two are related but not identical: Epithalamin contains multiple peptide fractions; Epitalon is a single, characterized sequence.
The sequence is short enough to cross cell membranes without a carrier protein. Khavinson's group proposed that AEDG binds directly to chromatin, specifically H1 histone subunits, and by doing so alters transcriptional access to aging-related genes. That mechanistic claim underpins much of the subsequent research in the area.
Researchers can view the Zurich Biotech compound catalog for Epitalon supply specifications, available vial sizes, and current COA data.
Mechanism: pineal regulation and telomerase activation
Two mechanisms appear most consistently in published Epitalon research.
The first is support for pineal melatonin synthesis. Melatonin output from the pineal gland declines substantially with age, contributing to circadian disruption, reduced antioxidant activity, and immune dysregulation. Animal experiments by the Khavinson group showed that Epithalamin treatment restored night-time melatonin secretion in aging rats toward levels measured in younger animals, with corresponding reductions in lipid peroxidation markers. Whether the isolated AEDG tetrapeptide produces this effect through the same pathway in the same magnitude as the full extract remains unresolved.
The second mechanism, and the one that draws most research attention, is telomerase activation. Telomerase is the ribonucleoprotein enzyme responsible for adding TTAGGG repeats to chromosome ends after cell division. Most differentiated somatic cells silence telomerase expression, so the progressive telomere shortening that occurs with each replication cycle sets an upper limit on cellular lifespan, a phenomenon documented in the Nobel Prize-winning work of Blackburn, Greider, and Szostak.
A 2003 study from Khavinson, Bondarev, and Butyugov, published in the Bulletin of Experimental Biology and Medicine (PMID 12937682), reported that Epitalon treatment induced hTERT expression (the catalytic subunit of human telomerase) in human fetal fibroblasts that had otherwise reached their replicative limit. Treated cultures extended their replicative capacity by approximately 42% relative to untreated controls. Telomere elongation was confirmed by Southern blot analysis of terminal restriction fragments.
A 2020 study by Khavinson et al., published in Molecules (PMC7037223), examined AEDG's effects on neurogenesis in human gingival mesenchymal stem cells. Treatment increased mRNA expression of neurogenic differentiation markers, specifically Nestin, GAP43, beta-Tubulin III, and Doublecortin, by 1.6 to 1.8 times. Molecular docking analysis indicated the peptide binds preferentially to H1/6 and H1/3 histone subunits at sites where histones contact DNA, providing a proposed epigenetic basis for the gene expression changes observed.
Animal evidence: lifespan and tumor studies
The most cited in vivo data comes from a 1998 paper by Anisimov, Mylnikov, and Khavinson in Mechanisms of Ageing and Development (PMID 9701766). Four animal cohorts received Epithalamin treatment starting in middle age: Drosophila melanogaster, SHR mice, C3H/Sn mice, and LIO rats. Mean lifespan increased 11 to 31% across the four groups. The authors attributed the effect to enhanced melatonin synthesis and reduced free radical accumulation in treated animals.
A 2003 follow-up by Anisimov and colleagues in Biogerontology (PMID 14501183) used synthetic Epitalon rather than the crude extract. Female SHR mice received monthly subcutaneous injections of 1.0 microgram per mouse beginning at 3 months of age and continuing until natural death. Maximum lifespan increased by 12.3% and the survival of the last 10% of the cohort extended by 13.3% relative to saline controls. Spontaneous leukemia incidence fell approximately sixfold in treated animals. Body weight and food consumption were unaffected, and no acute toxicity signs were recorded.
Two methodological points matter for interpreting these results. SHR mice are a hypertension-prone strain developed for cardiovascular research, not a standard aging model, so results in this strain may not transfer to wild-type cohorts. Both papers originated from the same laboratory. Independent replication of these lifespan findings by a separate group has not been published in a peer-reviewed journal.
Human-adjacent evidence: the Epithalamin clinical program
The human-level data most commonly cited alongside Epitalon actually concerns Epithalamin (the polypeptide extract), not the synthetic tetrapeptide. A 2003 review by Khavinson and Morozov in Neuroendocrinology Letters (PMID 14523363) summarized a 6-to-8-year clinical program enrolling 266 elderly participants. Those who received a combination of Thymalin (a thymic bioregulator) and Epithalamin showed a 4.1-fold reduction in mortality compared with controls, along with improved biomarkers across cardiovascular, endocrine, immune, and nervous system categories.
Attributing these results specifically to the AEDG tetrapeptide is not accurate. Epithalamin is a multi-fraction extract of undefined composition; its active components and their individual doses differ from a defined four-amino-acid sequence. The trial design also reflects 1980s-1990s Soviet clinical practice rather than modern randomized controlled trial standards. No peer-reviewed RCT of synthetic Epitalon administered to human subjects has been published in a major international journal indexed in PubMed.
Study limitations and the replication gap
The evidence base for Epitalon research has a structural problem: the vast majority of published findings, across in vitro, animal, and human-adjacent settings, originate from one institution and one principal investigator group. Peer review catches errors within individual papers, but independent replication by teams with no connection to the original work is what determines whether a finding generalizes. That step has not occurred for Epitalon.
The mechanistic story is internally consistent. hTERT activation, histone binding at H1 subunits, and melatonin pathway support are scientifically plausible and connect to well-studied aging biology. The animal lifespan data from 1998 and 2003 represents genuine controlled experiments. The gap lies between those animal and cell-culture findings and conclusions about human aging, a gap that no clinical trial has yet addressed.
For researchers evaluating Epitalon in 2026, the practical framing is this: the compound has credible in vitro and in vivo properties but lacks the independent confirmatory evidence that would place it among established geroprotective agents. Using the peptide dosing calculator to plan experimental protocols is straightforward; interpreting expected biological outcomes requires accounting for this translational uncertainty.
Handling and storage for Epitalon research
Epitalon arrives as a lyophilized white powder. At four amino acids and approximately 431 Da, it is among the smallest peptides in common research use. This relatively low molecular weight contributes to stability compared with longer sequences, though degradation still occurs under adverse temperature or light conditions.
Standard reconstitution with bacteriostatic water applies. Once reconstituted, the solution should be stored at 2 to 8 degrees C, protected from direct light, and used within 28 days of the first vial draw. For protocols requiring multiple doses over several weeks, preparing single-use aliquots at reconstitution reduces the total number of septum punctures and limits contamination risk.
Researchers based in Bali, Jakarta, Surabaya, or other equatorial locations should ensure cold-chain handling during transit. Ambient temperatures above 30 degrees C degrade reconstituted peptide within hours if no cooling is applied. The MOTS-c research overview covers handling considerations for another mitochondria-adjacent longevity-focused peptide, many of which apply equally to Epitalon.